Abbott Laboratories (ABT) Stock Forecast & Price Target

$116.78 +3.30 (+2.91%)

As of 01/21/2025 03:59 PM Eastern

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
0

Hold
4

Buy
11

Based on 15 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 4 have given a hold rating, and 11 have given a buy rating for ABT.

Consensus Price Target

$131.93
12.97% Upside

According to the 15 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $131.93. The highest price target for ABT is $149.00, while the lowest price target for ABT is $117.00. The average price target represents a forecasted upside of 12.97% from the current price of $116.78.

Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

ABT Analyst Ratings Over Time

Type	Current Forecast 1/23/24 to 1/22/25	1 Month Ago 12/24/23 to 12/23/24	3 Months Ago 10/25/23 to 10/24/24	1 Year Ago 1/23/23 to 1/23/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	12 Buy rating(s)	10 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$131.93	$130.71	$129.67	$119.31
Forecasted Upside	12.97% Upside	14.35% Upside	11.26% Upside	4.66% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.82	2.52
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	12.97% Upside	24,936.03% Upside	11.17% Upside
News Sentiment Rating	Positive News See Recent ABT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/21/2025	Royal Bank of Canada 4 of 5 stars	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$135.00 ➝ $135.00	+16.42%
1/2/2025	Evercore ISI 2 of 5 stars		Boost Target	Buy	$136.00	+19.76%
11/5/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$143.00 ➝ $149.00	+26.65%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$133.00 ➝ $138.00	+17.37%
10/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$143.00 ➝ $146.00	+24.14%
10/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$120.00 ➝ $125.00	+5.91%
10/17/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$115.00 ➝ $130.00	+10.34%
10/17/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$107.00 ➝ $117.00	-0.70%
10/17/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Maeder Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$131.00 ➝ $133.00	+12.88%
10/14/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Buy	$122.00 ➝ $129.00	+10.28%
Get the Latest News and Ratings for ABT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.
10/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$130.00	+14.69%
9/19/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$131.00	+14.04%
8/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$119.00 ➝ $127.00	+13.95%
7/30/2024	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$121.00	+20.11%
12/13/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$116.00 ➝ $121.00	+13.70%
7/21/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Peer Perform
4/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$118.00 ➝ $122.00	+9.56%
4/17/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$125.00 ➝ $130.00	+25.05%
3/31/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$90.00 ➝ $102.00	+2.95%
3/30/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$125.00 ➝ $115.00	+16.61%
1/26/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$110.00 ➝ $125.00	+12.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:07 AM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, January 20, 2025. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

Abbott Laboratories recently reported earnings of $1.21 per share, exceeding the consensus estimate of $1.20, indicating strong financial performance and effective management.
The company has a robust revenue of $10.64 billion for the latest quarter, surpassing analyst expectations, which reflects its solid market position and demand for its healthcare products.
Abbott Laboratories has increased its quarterly dividend from $0.55 to $0.59, demonstrating a commitment to returning value to shareholders, which can be attractive for income-focused investors.
The stock is currently trading at $113.45, which may present a buying opportunity given the analysts' target prices ranging from $129.00 to $133.00, suggesting potential upside.
With a consensus rating of "Moderate Buy" from analysts, and a majority rating the stock as a buy, investor sentiment appears positive, indicating confidence in the company's future performance.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

The stock has a relatively high P/E ratio of 34.48, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
Despite recent positive earnings, the company has a debt-to-equity ratio of 0.32, which, while manageable, indicates some reliance on debt financing that could pose risks in a rising interest rate environment.
Abbott Laboratories has a beta of 0.73, suggesting lower volatility compared to the market, which may limit potential gains during bullish market conditions.
Analysts have mixed ratings, with four holding a "hold" rating, indicating some uncertainty about the stock's short-term performance.
The stock's recent trading down by 0.4% could signal a lack of momentum, which may deter investors looking for immediate gains.

ABT Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $131.93, with a high forecast of $149.00 and a low forecast of $117.00.
: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABT shares.
: According to analysts, Abbott Laboratories's stock has a predicted upside of 12.97% based on their 12-month stock forecasts.
: Abbott Laboratories has been rated by research analysts at Barclays, Evercore ISI, and Royal Bank of Canada in the past 90 days.
: Analysts like Abbott Laboratories less than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.73 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:ABT) was last updated on 1/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Stock Forecast & Price Target